Core Viewpoint - The A-share market continues to experience fluctuations, with a notable divergence in popular sectors under the "cooling" expectations, leading to a pullback in cyclical and dividend sectors [1] Group 1: Market Performance - As of January 26, the CSI Dividend Index has a 40-day return difference of -8.89% compared to the Wind All A Index, indicating significant underperformance [1] - The latest dividend yield of the CSI Dividend Index is 5.06%, while the yield of the 10-year government bond is 1.82%, highlighting the relative value of high dividend configurations [1][14] Group 2: Banking Sector Insights - Eight banks, including China Merchants Bank and Shanghai Pudong Development Bank, reported 2025 performance forecasts, with seven showing growth in both operating income and net profit attributable to shareholders, indicating a stable industry development [1] - China Merchants Bank achieved an operating income of 337.5 billion yuan, remaining stable year-on-year, and a net profit of 150.2 billion yuan, reflecting a 1.2% increase [1] Group 3: Investment Strategies - Long-term funds, represented by insurance capital, are increasingly investing in high-dividend assets, particularly in the banking and public utility sectors, due to the scarcity of high-yield assets in a low-interest-rate environment [2][21] - The CSI Dividend ETF (515080) tracks high-dividend stocks, reflecting the overall performance of the A-share market's high-dividend stocks [2][6] Group 4: Future Outlook - The insurance capital's stake acquisitions reached a near 10-year high in 2025, driven by the low-interest-rate environment and the need for stable high-dividend assets [2][21] - The regulatory framework is encouraging long-term capital to enter the market, which may provide stability and mitigate concerns over interest rate differentials [22]

1月27日早盘，沪指盘中窄幅震荡上扬，创业板指等走高；小盘股整体疲弱，A股市场超4400股飘绿。 截至午间收盘，沪指微涨0.03%，深证成指跌0.37%，创业板指涨0.44%，科创50指数涨0.57%，中证 1000、中证2000指数跌超1%，沪深北三市合计成交约1.89万亿元。 华西证券认为，中长期视角下，本轮行情仍处中段，"慢牛"趋势有望延续。与2007年、2015年、2021年 高点相比，沪深300指数曾触及5300点—6000点区间，当前指数点位仅至中段；从大类资产比价的维 度，当前沪深300风险溢价5.27%，在近十年的几次行情中，风险溢价均降低至2.5%水平；从市值的角 度，A股总市值/M2、自由流通市值/居民存款的比重也均处于历史中枢附近，表明行情仍有充足空间与 机会。行业配置上，建议关注：科技产业行情扩散：如AI算力、AI应用、机器人、太空光伏、存储、 港股互联网等；受益于"反内卷"与涨价方向，如化工、有色金属等；年报业绩预告高增行业：如电子、 机械设备、医药等。 （文章来源：证券时报网） 盘面上看，农业、煤炭、钢铁、医药、石油、酿酒、电力等板块走低，保险、半导体板块强势拉升，银 行板块上扬， ...

Group 1 - The average salary increase for companies in 2026 is expected to slightly decrease to 4.0%, with the high-tech industry leading at 4.9% [1] - In 2025, 42.8% of companies implemented salary adjustments, down from 44.8% in 2024, with an overall salary increase of 4.1%, a decrease of 0.2 percentage points from 2024 [1] - The demand for AI talent is rising, with median monthly salaries for algorithm engineers nearing 25,000 yuan, and salaries for deep learning and natural language processing engineers also increasing [1][2] Group 2 - Salary increases for multi-modal algorithm engineers, autonomous driving algorithm engineers, machine learning engineers, and recommendation algorithm engineers exceed 23,000 yuan per month [2] - The pharmaceutical and healthcare industry shows a notable salary increase of 4.4%, while the finance and real estate sectors lag behind at 3.5% and 2.9%, respectively [2] - Salary increases for technical research and skilled professionals reach 5.3%, indicating that core talent driving innovation remains a priority for companies [2]

Consumption - Dongpeng Beverage has launched its H-share offering with a price not exceeding 248 HKD per share, expecting to end on January 29, and reported revenue exceeding 16.8 billion CNY for the first three quarters [2] - Xibei's founder, Jia Guolong, announced a return to core business focus, abandoning personal branding efforts, as the company faces losses exceeding 600 million CNY [2] - Yanghe Distillery anticipates a net profit decline of over 60% for 2025, primarily due to deep adjustments in the liquor industry and reduced market demand [2] - KFC has slightly raised prices on some delivery items by an average of 0.8 CNY starting January 26, while in-store prices remain unchanged [2] Technology - Jieyue Star has appointed Yin Qi as chairman, responsible for overall strategic direction and technology, and has reportedly completed a multi-billion B+ round of financing [2] - Samsung has raised NAND flash supply prices by 100% in Q1, indicating severe supply-demand imbalance in the semiconductor market [3] - AI chip supplier Aixin Yuanzhi has passed the Hong Kong Stock Exchange hearing [3] Health - Yiling Pharmaceutical expects a net profit of 1.2 to 1.3 billion CNY for 2025, driven by stable market performance in its cardiovascular and respiratory product lines [3] Mobility - Wuxi Xian Dao Intelligent Equipment has passed the Hong Kong Stock Exchange main board listing hearing, with CITIC Securities and JPMorgan as joint sponsors [4] - GAC Group has received nearly 2,000 orders for its GOVY AirCab by the end of 2025 [4] - Ideal Auto plans to close approximately 100 underperforming retail stores in a channel transformation effort [7] Health (Continued) - The first version of the commercial health insurance innovative drug directory took effect on January 1, 2026, aimed at providing more access to innovative drugs through commercial insurance [11] - Nine departments have issued a document encouraging innovative drugs to enter retail pharmacies, aiming to enhance the quality of the pharmaceutical retail industry [13]

Core Insights - The Chinese pharmaceutical industry has successfully transitioned from old to new growth drivers between 2015 and 2025, with innovation replacing generics and an enhanced ability to expand internationally [1] Group 1: Industry Transformation - The Chinese innovation sector has reached a significant scale, with traditional pharmaceutical companies successfully transforming into innovative entities, leading to the rapid rise of innovative drug companies [1] - The ability of Chinese pharmaceutical companies to expand internationally has accelerated, making them a key source of innovation for multinational corporations (MNCs), with medical devices and supply chains gaining a strong global presence [1] Group 2: Demand and Payment Dynamics - The aging population is accelerating, leading to an increased demand for chronic disease management [1] - Healthcare insurance revenue continues to grow steadily, while the National Healthcare Security Administration is actively promoting the development of commercial insurance to build a multi-tiered payment system [1] Group 3: Technological Advancements - New technologies are driving industry transformation, with the AI technology wave expected to unlock new growth logic in the pharmaceutical sector, including advancements in brain-computer interfaces, early cancer screening, and AI in healthcare [1] Group 4: Investment Opportunities - Looking ahead to 2026, there is continued optimism for the pharmaceutical technology sector, particularly those focused on innovation [1] Group 5: ETF Overview - The Vaccine ETF (159643) tracks the Vaccine Biotechnology Index (980015), which selects listed companies involved in vaccine research, production, and related services from the Shanghai and Shenzhen markets to reflect the overall performance of the vaccine industry chain [1]

Group 1 - The medical sector continues to decline, with the largest medical ETF (512170) dropping by 2.44%, losing multiple moving averages [1] - Despite the decline, there is active low-buying interest, as evidenced by a net subscription of 1.07 billion yuan over six consecutive trading days [1] - Eight out of ten component stocks of the medical ETF have reported positive earnings forecasts for 2025, with seven stocks expected to achieve double-digit growth [2][3] Group 2 - Notable earnings growth includes a projected increase of 214% to 371% for Zhaoyan New Drug, and both Boteng Co. and WuXi AppTec are expected to double their profits [2][3] - The CXO industry is expected to benefit from a recovering global investment environment and continued domestic support for innovative drug development, indicating a positive trend for the sector [2] - The medical ETF (512170) has a total fund size of 26.8 billion yuan, making it the largest in the market for medical ETFs [6]

Summary of Key Points from Conference Call Records Industry Overview - The pharmaceutical industry is experiencing mixed performance in the stock market, with the Shanghai Composite Index closing at 4132.61 points, down 0.09%, and the Shenzhen Component Index at 14316.64 points, down 0.85% [1][1] - The Shenwan Pharmaceutical Industry Index closed at 8648.35 points, up 0.29%, while the Hang Seng Healthcare Index in Hong Kong closed at 4032.36 points, down 1.58% [1][1] Company-Specific Insights Positive Performers - **Mikron Biotech**: Stock increased by 20.03% [1][1] - **Kepu Biotech**: Stock increased by 20.03% [1][1] - **Zhijiang Biotech**: Stock increased by 20.01% [1][1] - **Yixintang**: Expected net profit for 2025 is projected to be between 260 million to 330 million RMB, a significant increase of 127.79% to 189.12% year-on-year [4][5] - **Microchip Biotech**: Expected revenue for 2025 is 910 million RMB, a 38.32% increase, with a net profit turnaround to 53.46 million RMB from a loss of 115 million RMB [5][5] - **Tonghua Dongbao**: Expected net profit for 2025 is 1.242 billion RMB, recovering from a loss of 42.72 million RMB in the previous year [5][5] - **Minohua**: Expected net profit for 2025 is projected to be between 100 million to 123 million RMB, a significant increase of 49.69% to 84.11% [6][6] - **Sanofi Guojian**: Expected revenue for 2025 is projected to be 4.2 billion RMB, a substantial increase of 251.76% [7][7] Negative Performers - **Guangji Pharmaceutical**: Expected net loss for 2025 is projected to be between 518 million to 399 million RMB, a significant increase from a loss of 295 million RMB in the previous year [2][2] - **International Medicine**: Expected revenue for 2025 is projected to decline to 4.06 billion to 4.08 billion RMB, a 15.7% year-on-year decrease, with a net loss projected between 315 million to 295 million RMB [4][4] - **Huahai Pharmaceutical**: Expected net profit for 2025 is projected to decline by 70% to 80% from 1.119 billion RMB in the previous year [7][7] Regulatory Approvals - **Bohui Innovation**: Received medical device registration for a nucleic acid testing kit for reproductive tract pathogens [1][1] - **Hengrui Medicine**: Approved for clinical trials of SHR-1049 injection [2][2] - **Qianjin Pharmaceutical**: Received drug registration for aluminum magnesium carbonate chewable tablets [3][3] - **Wantai Biological Pharmacy**: HPV vaccine passed WHO PQ periodic review [4][4] - **Shisi Pharmaceutical Group**: Received new specification approval for compound potassium hydrogen phosphate injection [9][9] Additional Insights - The performance of the pharmaceutical sector is highly variable, with some companies showing significant growth while others are facing substantial losses. - Regulatory approvals are crucial for companies to enhance their product offerings and potentially improve financial performance in the future.

智通财经APP获悉，中信证券发布研报称，展望2026年医药投资趋势，无论是中国医药企业在创新领域 的集中兑现，还是政策端出台支持创新药械、优化集采、推动商保等一系列产业支持政策，医疗健康产 业的内外因催化因素都有望延续，医疗健康产业开始逐步重新回归到临床价值和需求导向的市场价格定 价体系，带来稳定且持续的国内医药市场环境和长坡厚雪的发展主基调，上市公司也有望迎来持续且稳 定的业绩增长趋势，带来行业成长高确定性的贝塔。 因此该行认为医药行业将是有望继续维持超配的行业，从横向维度上，建议2026年围绕以下几条主线进 行布局：1)创新驱动和国际化——在反内卷的国内政策环境下，关注创新驱动和国际化出海的相关标 的;2)自主可控——该行预计在未来可能还会陆续面临地缘政治扰动带来的风险，应更多关注自主可控 下核心零部件、试剂、科研上游的进口替代进程加速的相关标的;3)新政新气象——受益于集采优化、 医保三个支付、消费刺激政策和国企改革的相关标的。 中信证券主要观点如下： 25Q4/H2医疗健康产业整体来看业绩表现预期较为稳健，同时该行看到医药和医疗企业的创新正在加速 兑现为业绩端的增长 该行对重点覆盖的76家医药公司25 ...

Group 1: Hotel Industry Insights - The hotel industry is entering a new phase characterized by non-linear growth among leading players, driven by expectations of cyclical turning points and capital consolidation, with a long-term focus on scale and efficiency [17][18] - The valuation of hotels follows a three-dimensional framework: macro supply-demand mismatches determine valuation turning points, structural upgrades amplify volatility, and individual company cycles provide alpha opportunities [17] - The current cycle's bottom is marked by increased differentiation within the industry, with leading hotels expected to see RevPAR (Revenue per Available Room) recover as supply stabilizes and demand rebounds, particularly in leisure travel [17][18] Group 2: Social Services Sector - The social services sector has seen a 1.52% increase during the reporting period, outperforming the broader market by 2.71 percentage points, with notable stocks including Tongdao Liepin and Keri International [19][20] - The sector is actively responding to the silver economy, with policies promoting the development of elderly care services and companies like New Oriental launching local interest courses for retirees [21] - The Spring Festival is expected to drive significant travel demand, with predictions of approximately 95 million air passengers during the holiday period, indicating a strong recovery in travel-related services [21] Group 3: Food and Beverage Sector - The food and beverage sector has experienced a decline of 1.37%, with A-share food and beverage indices falling by 1.57%, while H-share indices showed a slight increase [26] - The sector is characterized by differentiated performance, with alcoholic beverages, particularly baijiu, showing stable prices and a focus on demand recovery during the Spring Festival [27] - Recommendations include leading companies in various categories, such as Moutai for baijiu, Yili for dairy, and Nongfu Spring for beverages, highlighting their strong growth potential and market positioning [27][28] Group 4: Pharmaceutical Industry - The pharmaceutical industry is witnessing a robust outflow of innovative drugs and a recovery in the CXO sector, driven by favorable clinical data and supportive policies [33][34] - The domestic supply-demand landscape remains stable, with a focus on innovative drug forms and technologies such as AI in healthcare and brain-machine interfaces, which are expected to see significant growth [35] - Investment recommendations include companies with strong competitive advantages in innovation and cost control, such as Mindray Medical and WuXi AppTec [35][36]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：明察宏观 文 财信研究院宏观团队 李沫 胡文艳 伍超明 核心观点 一、价比量更重要：经济、政策以及资产配置新瞄点 其一，价格直接牵动企业盈利与居民收入，是激活"价格-盈利-收入-消费"内循环的关键枢纽，比GDP等 总量指标更能反映经济内生活力。其二，当前"量增价缩"格局不可持续，推动价格回升至合理区间已是 宏观政策必然选择，否则将侵蚀供需两端并阻碍新质生产力发展。其三，A股市场未来的走势，核心在 于建立"价格-盈利-信心"正向循环，价格回升既是启动盈利修复的关键，也是稳定市场预期的压舱石。 二、2026年价格走势分析 （一）趋势研判：2026年物价回升趋势明确。从宏观视角看，供需缺口趋于收敛、M1增速触底回升、 居民就业筑底改善以及产能周期有望上行等四大领先指标，共同为物价回升奠定基础。从价格构成看， 2026年CPI与PPI的"翘尾因素"将显著高于上年；同时"十五五"开局之年，扩大内需政策与供给侧"反内 卷"政策有望形成合力，共同支撑"新涨价因素"，推动价格实现温和回升。 （二）核心判断：上游主导PPI回升，预计2026年二季度 ...